Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on September 5, 2025, with the report date finalized on September 9, 2025. The filing primarily addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation.
Material Changes
- Board Appointment: The Board of Directors appointed Stephen DeNelsky as a Class I director, effective September 5, 2025. His term expires at the 2028 annual meeting.
- Committee Assignment: Mr. DeNelsky was appointed to the Nominating & Governance Committee.
- Compensation Structure: Mr. DeNelsky will receive standard non-employee director compensation valued at approximately $135,000, consisting of:
- An equity award of 110,000 restricted stock units (RSUs).
- An annual cash retainer of $91,000.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies were disclosed in this report. The appointment of Mr. DeNelsky, who brings 30 years of healthcare industry experience including roles at Oaktree Capital Management and Marathon Asset Management, is intended to strengthen board oversight.
Investor Verification Checklist
- Verify the impact of the 110,000 RSU grant on total share count and potential dilution.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the absence of any undisclosed family relationships or prior arrangements between Mr. DeNelsky and existing management.
- Check subsequent filings for the company's next scheduled financial report to assess operational performance, as this 8-K contains no financial data.